Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to HN2010000108ApriorityCriticalpatent/HN2010000108A/en
Publication of HN2010000108ApublicationCriticalpatent/HN2010000108A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
ESTA INVENCION SE REFIERE UN COMPUESTO DE FORMULA (I) EN LA QUIE UNO DE A1., A2 O A3 ES N, Y LOS OTROS SE SELECCIONAN INDEPENDIENTEMENTE DE CH O N; EL ANILLO B ES UN ANILLO CARBOCICLICO O HETEROCICCO DE 5 O 6 MIEMBROS CONDENSADO QUE ESTA OPCIONALMENTE SUSTITUIDO COMO SE DEFINE EN LA MEMORIA DESCRITIVA Y R1, R2, R3, R4 Y N SON COMO SE DEFINE EN LA MEMORIA DESCRIPTIVA. LOS COMPUESTOS SON INHIBIDORES DE EPHB4 O EPHA2, Y POR LO TANTO PUEDEN SER UTILES EN COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE AFECCIONES TALES COMO EL CANCER.THIS INVENTION REFERS A FORMULA COMPOUND (I) IN WHICH ONE OF A1., A2 OR A3 IS N, AND THE OTHER ARE SELECTED INDEPENDENTLY FROM CH OR N; RING B IS A CARBOCYCLIC OR HETEROCICTIC RING OF 5 OR 6 MEMBERS CONDENSED THAT IT IS OPTIONALLY REPLACED AS DEFINED IN THE DESCRITIVE MEMORY AND R1, R2, R3, R4 AND N ARE AS DEFINED IN THE DESCRIPTIVE MEMORY. THE COMPOUNDS ARE INHIBITORS OF EPHB4 OR EPHA2, AND THEREFORE THEY CAN BE USEFUL IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AFFECTION SUCH AS CANCER.
Compounds derived from 5-alkynyl-pyrimidines, kinase inhibitors; pharmaceutical compositions containing them; and its use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.